How to buy Hepion Pharmaceuticals stock | $2.18

Hepion Pharmaceuticals, Inc is a biotechnology business based in the US. Hepion Pharmaceuticals shares (HEPA) are listed on the NASDAQ and all prices are listed in US Dollars. Hepion Pharmaceuticals employs 12 staff and has a market cap (total outstanding shares value) of USD$69.5 million.

How to buy shares in Hepion Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Hepion Pharmaceuticals. Find the stock by name or ticker symbol: HEPA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Hepion Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.18, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Hepion Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Hepion Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Hepion Pharmaceuticals share price

Use our graph to track the performance of HEPA stocks over time.

Hepion Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$2.18
52-week range	USD$1 - USD$6.9
50-day moving average	USD$2.1447
200-day moving average	USD$3.0519
Wall St. target price	USD$10
PE ratio	0.3728
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-50.579

Buy Hepion Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Hepion Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Hepion Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Hepion Pharmaceuticals price performance over time

Historical closes compared with the close of $2.18 from 2021-01-11

1 week (2021-01-11)	2.18
1 month (2020-12-18)	12.37%
3 months (2020-10-16)	-36.26%
6 months (2020-07-17)	-41.08%

1 year (2020-01-17)	-62.02%
2 years (2019-01-18)	550.75%
3 years (2018-01-18)	587.70%
5 years (2016-01-15)	118.00%

Is Hepion Pharmaceuticals under- or over-valued?

Valuing Hepion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hepion Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Hepion Pharmaceuticals's P/E ratio

Hepion Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Hepion Pharmaceuticals shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Hepion Pharmaceuticals financials

Gross profit TTM	USD$0
Return on assets TTM	-52.6%
Return on equity TTM	-118.85%
Profit margin	0%
Book value	$4.201
Market capitalisation	USD$69.5 million

TTM: trailing 12 months

Shorting Hepion Pharmaceuticals shares

There are currently 203,488 Hepion Pharmaceuticals shares held short by investors – that's known as Hepion Pharmaceuticals's "short interest". This figure is 43.4% down from 359,445 last month.

There are a few different ways that this level of interest in shorting Hepion Pharmaceuticals shares can be evaluated.

Hepion Pharmaceuticals's "short interest ratio" (SIR)

Hepion Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Hepion Pharmaceuticals shares currently shorted divided by the average quantity of Hepion Pharmaceuticals shares traded daily (recently around 3.4 million). Hepion Pharmaceuticals's SIR currently stands at 0.06. In other words for every 100,000 Hepion Pharmaceuticals shares traded daily on the market, roughly 60 shares are currently held short.

However Hepion Pharmaceuticals's short interest can also be evaluated against the total number of Hepion Pharmaceuticals shares, or, against the total number of tradable Hepion Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hepion Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Hepion Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0064% of the tradable shares (for every 100,000 tradable Hepion Pharmaceuticals shares, roughly 6 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hepion Pharmaceuticals.

Find out more about how you can short Hepion Pharmaceuticals stock.

Hepion Pharmaceuticals share dividends

We're not expecting Hepion Pharmaceuticals to pay a dividend over the next 12 months.

Have Hepion Pharmaceuticals's shares ever split?

Hepion Pharmaceuticals's shares were split on a 1:70 basis on 3 June 2019. So if you had owned 70 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Hepion Pharmaceuticals shares – just the quantity. However, indirectly, the new 6900% higher share price could have impacted the market appetite for Hepion Pharmaceuticals shares which in turn could have impacted Hepion Pharmaceuticals's share price.

Hepion Pharmaceuticals share price volatility

Over the last 12 months, Hepion Pharmaceuticals's shares have ranged in value from as little as $1 up to $6.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hepion Pharmaceuticals's is 1.4509. This would suggest that Hepion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Hepion Pharmaceuticals overview

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Frequently asked questions

• What percentage of Hepion Pharmaceuticals is owned by insiders or institutions?

  Currently 6.619% of Hepion Pharmaceuticals shares are held by insiders and 13.783% by institutions.

• How many people work for Hepion Pharmaceuticals?

  Latest data suggests 12 work at Hepion Pharmaceuticals.

• When does the fiscal year end for Hepion Pharmaceuticals?

  Hepion Pharmaceuticals's fiscal year ends in December.

• Where is Hepion Pharmaceuticals based?

  Hepion Pharmaceuticals's address is: 399 Thornall Street, Edison, NJ, United States, 08837

• What is Hepion Pharmaceuticals's ISIN number?

  Hepion Pharmaceuticals's international securities identification number is: US4268971045

• What is Hepion Pharmaceuticals's CUSIP number?

  Hepion Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 21234W103